Top

Published in:

Open Access 01-12-2008 | Research

Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells

Authors: Nadia Vié, Virginie Copois, Caroline Bascoul-Mollevi, Vincent Denis, Nicole Bec, Bruno Robert, Caroline Fraslon, Emmanuel Conseiller, Franck Molina, Christian Larroque, Pierre Martineau, Maguy Del Rio, Céline Gongora

Published in: Molecular Cancer | Issue 1/2008

Abstract

Background

Colorectal cancer (CRC) is one of the most common causes of cancer death throughout the world. In this work our aim was to study the role of the phosphoserine aminotransferase PSAT1 in colorectal cancer development.

Results

We first observed that PSAT1 is overexpressed in colon tumors. In addition, we showed that after drug treatment, PSAT1 expression level in hepatic metastases increased in non responder and decreased in responder patients.

In experiments using human cell lines, we showed that ectopic PSAT1 overexpression in colon carcinoma SW480 cell line resulted in an increase in its growth rate and survival. In addition, SW480-PSAT1 cells presented a higher tumorigenic potential than SW480 control cells in xenografted mice. Moreover, the SW480-PSAT1 cell line was more resistant to oxaliplatin treatment than the non-transfected SW480 cell line. This resistance resulted from a decrease in the apoptotic response and in the mitotic catastrophes induced by the drug treatment.

Conclusion

These results show that an enzyme playing a role in the L-serine biosynthesis could be implicated in colon cancer progression and chemoresistance and indicate that PSAT1 represents a new interesting target for CRC therapy.

Available only for authorised users

Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell. 1996, 87: 159-170.CrossRefPubMed

Galamb O, Sipos F, Fischer K, Tulassay Z, Molnar B: The results of the expression array studies correlate and enhance the known genetic basis of gastric and colorectal cancer. Cytometry B Clin Cytom. 2005, 68: 1-17.CrossRefPubMed

Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004, 22: 23-30.CrossRefPubMed

Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised tria. Lancet. 2000, 355: 1041-7.CrossRefPubMed

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004, 350: 2335-42.CrossRefPubMed

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004, 351: 337-45.CrossRefPubMed

Tai IT, Dai M, Owen DA, Chen LB: Genome-wide expression analysis of therapy-resistant tumors reveals sparc as a novel target for cancer therapy. J Clin Invest. 2005, 115: 1492-502.PubMedCentralCrossRefPubMed

Schmidt WM, Kalipciyan M, Dornstauder E, Rizovski B, Steger GG, Sedivy R, Mueller MW, Mader RM: Dissecting progressive stages of 5-fluorouracil resistance in vitro using rna expression profiling. Int J Cancer. 2004, 112: 200-12.CrossRefPubMed

Samimi G, Manorek G, Castel R, Breaux JK, Cheng TC, Berry CC, Los G, Howell SB: cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemother Pharmacol. 2005, 55: 1-11.CrossRefPubMed

10.

Arango D, Wilson AJ, Shi Q, Corner GA, Aranes MJ, Nicholas C, Lesser M, Mariadason JM, Augenlicht LH: Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer. 2004, 91: 1931-46.PubMedCentralCrossRefPubMed

11.

Baek JY, Jun DY, Taub D, Kim YH: Characterization of human phosphoserine aminotransferase involved in the phosphorylated pathway of l-serine biosynthesis. Biochem J. 2003, 373: 191-200.PubMedCentralCrossRefPubMed

12.

Ojala P, Sundstrom J, Gronroos JM, Virtanen E, Talvinen K, Nevalainen TJ: mRNA differential display of gene expression in colonic carcinoma. Electrophoresis. 2002, 23: 1667-76.CrossRefPubMed

13.

Friederichs J, Rosenberg R, Mages J, Janssen K, Maeckl C, Nekarda H, Holzmann B, Siewert JR: Gene expression profiles of different clinical stages of colorectal carcinoma: toward a molecular genetic understanding of tumor progression. Int J Colorectal Dis. 2005, 20: 391-402.CrossRefPubMed

14.

Martens JWM, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, Portengen H, Meijer-Van Gelder ME, Piepenbrock C, Olek A, Hofler H, Kiechle M, Klijn JGM, Schmitt M, Maier S, Foekens JA: Association of dna methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res. 2005, 65: 4101-17.CrossRefPubMed

15.

Okada H, Mak TW: Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer. 2004, 4: 592-603.CrossRefPubMed

16.

Fujie Y, Yamamoto H, Ngan CY, Takagi A, Hayashi T, Suzuki R, Ezumi K, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Monden M: Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn J Clin Oncol. 2005, 35: 453-63.CrossRefPubMed

17.

Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T, Hashimoto-Tamaoki T: Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res. 2001, 61: 1029-37.PubMed

18.

Motwani M, Jung C, Sirotnak FM, She Y, Shah MA, Gonen M, Schwartz GK: Augmentation of apoptosis and tumor regression by flavopiridol in the presence of cpt-11 in HCT116 colon cancer monolayers and xenografts. Clin Cancer Res. 2001, 7: 4209-19.PubMed

19.

Roninson IB, Broude EV, Chang BD: If not apoptosis, then what? treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat. 2001, 4: 303-13.CrossRefPubMed

20.

Zhang H, Gu Y, Li Z, Jia Y, Yuan L, Li S, An GS, Ni JH, Jia HT: Exposure of human lung cancer cells to 8-chloro-adenosine induces G2/M arrest and mitotic catastrophe. Neoplasia. 2004, 6: 802-12.PubMedCentralCrossRefPubMed

21.

de Koning TJ, Snell K, Duran M, Berger R: Poll-The B, Surtees R. L-serine in disease and development. Biochem J. 2003, 371: 653-61.PubMedCentralCrossRefPubMed

22.

Cara CJ, Pena AS, Sans M, Rodrigo L, Guerrero-Esteo M, Hinojosa J, Garcia-Paredes J, Guijarro LG: Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Monit. 2004, 10: RA247-54.PubMed

23.

Eagle H: Amino acid metabolism in mammalian cell cultures. Science. 1959, 130: 432-7.CrossRefPubMed

24.

Maxwell M, MCCoy TA, Neuman RE: The amino acid requirements of the walker carcinosarcoma 256 in vitro. Cancer Res. 1956, 16: 979-84.PubMed

25.

Snell K, Natsumeda Y, Eble JN, Glover JL, Weber G: Enzymic imbalance in serine metabolism in human colon carcinoma and rat sarcoma. Br J Cancer. 1988, 57: 87-90.PubMedCentralCrossRefPubMed

26.

Del Rio M, Molina F, Bascoul-Mollevi C, Copois V, Bibeau F, Chalbos P, Bareil C, Kramar A, Salvetat N, Fraslon C, Conseiller E, Granci V, Leblanc B, Pau B, Martineau P, Ychou M: Gene Expression Signature for the Prediction of Response to Leucovorin, Fluorouracil, and Irinotecan in Advanced Colorectal Cancer Patients. J Clin Oncol. 2007, 25: 773-780.PubMedCentralCrossRefPubMed

27.

Copois V, Bibeau F, Bascoul-Mollevi C, Salvetat N, Chalbos P, Bareil C, Candeil L, Fraslon C, Conseiller E, Granci V, Maziere P, Kramar A, Ychou M, Pau B, Martineau P, Molina F, Del Rio M: Impact of RNA degradation on gene expression profiles: assessment of different methods to reliably determine RNA quality. J Biotechnol. 2006, 127: 549-59.CrossRefPubMed

28.

Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990, 82: 1107-12.CrossRefPubMed

Title: Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells
Authors: Nadia Vié
Virginie Copois
Caroline Bascoul-Mollevi
Vincent Denis
Nicole Bec
Bruno Robert
Caroline Fraslon
Emmanuel Conseiller
Franck Molina
Christian Larroque
Pierre Martineau
Maguy Del Rio
Céline Gongora
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2008
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-7-14

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2008

In Silico analysis of Gastric carcinoma Serial Analysis of Gene Expression libraries reveals different profiles associated with ethnicity

DNA repair gene ERCC2 polymorphisms and associations with breast and ovarian cancer risk

Insulin-like growth factor-I gene therapy reverses morphologic changes and reduces hyperprolactinemia in experimental rat prolactinomas

Altered splicing of CEACAM1 in breast cancer: Identification of regulatory sequences that control splicing of CEACAM1 into long or short cytoplasmic domain isoforms

Metabolite profiling of human colon carcinoma – deregulation of TCA cycle and amino acid turnover

Rac1 GTPase and the Rac1 exchange factor Tiam1 associate with Wnt-responsive promoters to enhance beta-catenin/TCF-dependent transcription in colorectal cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer